14.Jan 26
Deals
La Tour International advises FineHeart in connection with the second closing of its Series C

Paul-Albert Legrand and Mathilde Celestin advised FineHeart in connection with the second closing of its Series C financing. This new tranche, amounting to €35 million, brings together new investors, including Groupe Pasteur Mutualité and Groupe Etchart, alongside existing investors, notably the European Innovation Council (EIC) Fund, FH Founders, Lurra Capital, IRDI Capital Investissement, Nouvelle Aquitaine Co-Investissement (NACO) and Groupe Doliam.

FineHeart is a French clinical-stage medtech company specializing in the development of innovative implantable medical devices for the treatment of severe heart failure.

La Tour International
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

This site is registered on wpml.org as a development site.